Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05955105
Other study ID # CILB2109A102
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 25, 2023
Est. completion date July 24, 2026

Study information

Verified date May 2024
Source Innolake Biopharm
Contact Xue Wang
Phone 86-021-38863266
Email xue.wang@innolakebio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.


Description:

This is a two-part study consists of dose escalation and expansion in selected indications. The dose escalation part adopts a 3+3 protocol design and consists of 2 cohorts. Based on the data obtained from the escalation study, selected dose cohort will be expanded in 10 tumor types to further investigate the efficacy of the combination therapy. Subjects will be assessed for safety and efficacy outcomes at pre-specified time points.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date July 24, 2026
Est. primary completion date January 25, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Adult patients between the ages of 18 and 80 years. 2. Patients with histologically or cytologically confirmed solid tumours that are advanced, metastatic and or progressive, for whom there is no effective standard therapy available. 3. Eastern Collaborative Oncology Group (ECOG) Performance Status of =2. 4. Expected life expectancy =3 months. 5. Evaluable disease, either measurable on imaging, or with informative tumour marker(s), as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Eisenhauer, et al. 2009). 6. Laboratory values at Screening: Absolute neutrophil count =1.5 x 109/L; Platelets =75 x 109/L; Hemoglobin = 90g/L; Total bilirubin <1.5 times the upper limit of normal; Aspartate aminotransferase (AST) =3 times the upper limit of normal, = 5 times the upper limit of normal if subject has hepatic malignancies; Alanine aminotransferase (ALT) =2.5 times the upper limit of normal, = 5 times the upper limit of normal if subject has hepatic malignancies; Estimated glomerular filtration rate (GFR) of >50 mL/min (based on the Cockcroft-Gault formula; International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT) =1.5 times the upper limit of normal; Left Ventricular Ejection Fraction (LVEF) = 50%; Corrected QT Interval by Fridericia Method: male<450ms, female<470ms; and 7. Negative human chorionic gonadotropin (hCG) test in women of childbearing potential. 8. Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control (e.g. barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices) during the entire duration of the study and for 90 days after final administration of ILB-2109, or the patient must be surgically sterile . 9. Ability to give written, informed consent prior to any study-specific Screening procedures. Exclusion Criteria: 1. In the past 3 weeks: received systemic anti-tumor therapy, including chemotherapy, radiation, biologics, androgen, targeted therapy and immunotherapy with the following exceptions: i. received treatment containing nitrosoureas or mitomycin C in the past 6 weeks; ii. received oral fluorouracil or small molecule targeted therapy or Chinese Traditional Medicine (CTM) with anti-neoplasm indication in the past 2 weeks ; 2. In the past 4 weeks: received any other investigational treatment; 3. Gastrointestinal disease (e.g. Crohn's disease, ulcerative colitis, or short gut syndrome) that would impact on drug absorption; 4. Uncontrollable third-spacing of fluids; 5. Known CNS metastasis with clinical symptoms or the need of steroid treatment or CNS lesion = 1.5cm or with the evidence of lesion enlargement in the past 4 weeks; 6. Severe cardiovascular diseases including symptomatic heart failure (NYHA Class II and above), unstable angina, arrythmia, myocardial infarction within the past 6 months, embolism or pulmonary embolism within the past 3 months; 7. Having any risk factors of QT prolongation, including present or family history of long QT syndrome or using any medication with known QT prolongation effect; 8. Poor controlled chronic diseases, including poorly controlled diabetes mellitus (defined as HbA1c = 8.5%), poorly controlled hypertension, has a history of hypertensive emergency or hypertensive encephalopathy, endocrine diseases that require systemic therapy; 9. Current diagnosis of interstitial pneumonia or a history of chronic emphysema, COPD, or TB infection; 10. Autoimmune diseases that required systemic therapy within the past 2 years, with the exception of vitiligo, asthma, atopic diseases and autoimmune thyroid diseases that are stable on thyroid replacement therapy; 11. Active infection with the need if IV antibiotic treatment; 12. Known HIV infection; 13. Active HBV infection (defined as positive HBsAg and HBV-DNA>500 IU/ml), active HCV infection (positive HCV antibody but HCV-RNA < lower limit of detection is allowed to participate); 14. Known syphilis infection; 15. Received systemic steroid at a dose greater or equivalent to 10mg of prednisone per day or other immune modulating treatments in the past 14 days; 16. Plan to receive live vaccine during the study period (4 weeks prior to the 1st dose till 6 months after the last dose); 17. Major surgery within the past 4 weeks; 18. Previous allogeneic bone marrow transplant or solid organ transplant; 19. Known history of psychiatric disease/alcohol or drug abuse that would affect subject's compliance to trial protocol; 20. Any unresolved toxicities from prior therapies higher than CTCAE grade 1 with the following exceptions: i. alopecia; ii. peripheral neuropathy; iii. thyroid function abnormalities that can be treated with replacement therapy; 21. Known history of CTCAE grade 3 and above irAE in previous immunotherapies; 22. Known allergy to ILB-2109 or Toripalimab; 23. Subjects who are currently pregnant or breastfeeding; 24. Other conditions that in the opinion of the investigator will make the subject unfit to participate in this trial;

Study Design


Intervention

Drug:
ILB-2109
ILB-2109 tablets will be administered by mouth every day in 21-day cycles
Toripalimab
Toripalimab injection will be administered via IV every 21 days.

Locations

Country Name City State
China Shandong Cancer Hospital JiNan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Innolake Biopharm

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other pCREB level in PBMC Study the pharmacodynamic characteristics of ILB-2109 tablets, including the relationship between drug plasma concentration and the level of pCREB in PBMC. 36 months
Other Expression level of Adnosine Signature gene panel Investigate potential biomarkers including the expression level of AdenoSig in tumor tissues 36 months
Other Tumor Mutational Burden Investigate potential biomarkers including the TMB in tumor tissues 36 months
Other MSI Status Investigate potential biomarkers including the MSI status in relationship to efficacy outcomes 36 months
Other PD-L1 Investigate potential biomarkers including the expression level of PD-L1 in tumor tissues 36 months
Other CD68 Investigate potential biomarkers including the expression level of CD68 in tumor tissues 36 months
Other A2aR Investigate potential biomarkers including the expression level of A2aR in tumor tissues 36 months
Other CD8 Investigate potential biomarkers including the expression level of CD8 in tumor tissues 36 months
Primary The Incidence of DLTs The incidence rate of Dose Limiting Toxicities (DLTs) Cycle 1 (21 days)
Primary MTD Determine the maximum tolerated dose (MTD) of ILB-2109 tablets 6 months
Primary RP2D Determine the recommended phase 2 dose (RP2D) when used in combination with Toripalimab for subsequent studies 6 months
Primary The Objective Response Rate (ORR) Observe the Objective Response Rate (ORR) of ILB-2109 tablets combined with Toripalimab in prespecified cohorts 36 months
Secondary AE/TEAE/drug-related TEAE/irAE/SAE Incidence of AE/TEAE/drug-related TEAE/irAE/SAE graded by CTCAE 5.0 36 months
Secondary Lab Abnormalities Incidence of lab/physcial/EKG/vitals abnormalities graded by CTCAE 5.0 36 months
Secondary Peak Plasma Concentration (Cmax) Study the Peak Plasma Concentration of ILB-2109 tablets 36 months
Secondary Area under the plasma concentration versus time curve (AUC) Study the Area under the plasma concentration versus time curve (AUC) of ILB-2109 tablets 36 months
Secondary Half Life (T1/2) Study the Half Life (T1/2) of ILB-2109 tablets 36 months
Secondary Time to maximum plasma concentration (Tmax) Study the Time to maximum plasma concentration (Tmax) of ILB-2109 tablets 36 months
Secondary Clearance (CL) Study the Clearance (CL) of ILB-2109 tablets 36 months
Secondary Volume of Distribution (Vd) Study the Volume of Distribution (Vd) of ILB-2109 tablets 36 months
Secondary Progression Free Survival (PFS) Observe the Progression Free Survival (PFS) in prespecified cohorts 36 months
Secondary Overall Survival (OS) Observe the Overall Survival (OS) in prespecified cohorts 36 months
Secondary Duration of Response (DOR) Observe the Duration of Response (DOR) in prespecified cohorts 36 months
Secondary Disease Control Rate (DCR) Observe the Disease Control Rate (DCR) in prespecified cohorts 36 months
Secondary Time to Progression (TTP) Observe the Time to Progression (TTP) in prespecified cohorts 36 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2